GLP-1 RAs may address this directly Tirzepatide (dual GIP/GLP-1) appears to achieve the greatest weight reduction (1624% in non-diabetic patients) GLP-1 RAs may reduce or enable tapering of systemic immunosuppressants (including methotrexate and biologics) in patients who achieve significant weight loss, reducing cumulative toxicity
The International Menopause Society endorses testosterone therapy for postmenopausal women with low sexual desire
Food and Drug Administration (FDA) has approved the first prescription medication specifically for treating obstructive sleep apnea (OSA): the weight-loss drug Zepbound
[10] [12] Reviews caution that the size of the effect depends on the fiber type, dose, and individual microbiome, so it's real but not a megadose miracle
As research evolves, were likely to see even more advanced peptide blends and delivery methods that make treatment easier, faster, and more personalized
This dramatic reversal highlights the inherent risks of operating in the highly regulated pharmaceutical space, especially when challenging established players with patent-protected products
